CENTRAL NERVOUS SYSTEM ANTIGEN’S EPITOPES SELECTION, WHICH TAKE PART IN MULTIPLE SCLEROSIS PATIENTS AUTOIMMUNE REACTIONS, AS A WAY OF A SPECIFIC TOLEROGENITY CREATION

G. N Bisaga; V. S Chirsky; I. A Baldueva; T. L Nechaeva

doi:10.23868/201906015

Genes & Cells ›› 2019, Vol. 14 ›› Issue (2) : 26 -31. DOI: 10.23868/201906015

Articles

research-article

CENTRAL NERVOUS SYSTEM ANTIGEN’S EPITOPES SELECTION, WHICH TAKE PART IN MULTIPLE SCLEROSIS PATIENTS AUTOIMMUNE REACTIONS, AS A WAY OF A SPECIFIC TOLEROGENITY CREATION

Author information +

History +

PDF

Abstract

To determine the central nervous system (CNS) peptide epitopes that take part in multiple sclerosis (MS) immune response, and taking into consideration the literature, we selected CNS peptides that most likely participated in MS immune response: MBP1 (83-99), MBP2 (111-129), MBP3 (146-170), PLP, and MOG. We estimated the specific activation of serum T-cells by the level of detected cytokines in 6 MS patients: 3 - with relapsing-remitting MS (RRMS), 2 - primary progressive MS (PPMS), 1 - secondary progressive MS (SPMS). As a result we revealed that all selected peptides took part in MS immunopathogenesis: in all patients MBP1 and PLP were involved; MBP2, MBP3, and MOG - in 5 of 6 patients. In response to CNS peptides T-cells most actively produced INFg, in a less degree - IL10 and IL4. In 5 of 6 cases we found negative correlation between levels of INFg and IL10. Cytokine levels did not differ between RRMS, PPMS and SPMS. Our results confirm the immunological phenomenon of epitope spreading that affects the efficacy of MS treatment, including immunological tolerance restoration.

Keywords

ELISpot / multiple sclerosis / diagnosis / pathogenesis / autoimmunity / immunological tolerance / dendritic cells / cell therapy

Cite this article

Download citation ▾

G. N Bisaga, V. S Chirsky, I. A Baldueva, T. L Nechaeva. CENTRAL NERVOUS SYSTEM ANTIGEN’S EPITOPES SELECTION, WHICH TAKE PART IN MULTIPLE SCLEROSIS PATIENTS AUTOIMMUNE REACTIONS, AS A WAY OF A SPECIFIC TOLEROGENITY CREATION. Genes & Cells, 2019, 14(2): 26-31 DOI:10.23868/201906015

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	Бойко А.Н., Гусев Е.И. Современные алгоритмы диагностики и лечения рассеянного склероза, основанные на индивидуальной оценке состояния пациента. Журн. неврологии и психиатрии им. C.C. Корсакова 2017; 117(2): 92-106.

[2]	Бисага Г.Н., Гайкова О.Н., Онищенко Л.С. и др. Рассеянный склероз: от морфологии к патогенезу. Санкт-Петербург, 2015: 104.

[3]	Xiao B.G., Huang Y.M., Link H. Tolerogenic Dendritic Cells: The Ins and Outs of Outcome. J. Immunother. 2006; 29: 465-71.

[4]	Одинак М.М., Чирский В.С., Бисага Г.Н. и др. Аутологичные IL-10-модифицированные дендритные клетки в иммунотерапии рассеянного склероза: первый клинический опыт. Клеточная трансплантология и тканевая инженерия 2008; 4: 60-5.

[5]	Lutz M.B., Schuler G. Immature, semi-mature and fully mature dendritic cells: which signals induce tolerance or immunity? Trends Immunol. 2002; 23: 445-9.

[6]	Steinman R.M., Hawiger D., Nussenzweig M.C. Tolerogenic dendritic cells. 2003; 21: 685-711.

[7]	Duan R.S., Link H., Xiao B.G. Long-term effects of IFN-g, IL-10 and TGF-a-modulated dendritic cells on immune response in Lewis rats. J. Clin. Immunol. 2005; 25: 50-6.